[Skip to Content]
[Skip to Content Landing]
Views 1,168
Citations 0
Editorial
May 18, 2020

Risk of Neuroinflammatory Adverse Events With Tumor Necrosis Factor Inhibitor Treatment

Author Affiliations
  • 1Division of Neuroimmunology and Glial Biology, Department of Neurology, University of California, San Francisco, San Francisco
  • 2Rheumatology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco
JAMA Neurol. Published online May 18, 2020. doi:10.1001/jamaneurol.2020.1160

Tumor necrosis factor (TNF) inhibitors have been widely used for the treatment of autoimmune disease since 1998, when the first biological agents were licensed in the United States.1 Several biosimilar versions are now available.2 These therapies target the TNF receptor (infliximab, adalimumab, certolizumab pegol, and golimumab) or its soluble form (etanercept) to modulate immune function.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×